Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
2.06B
Market cap2.06B
Price-Earnings ratio
-4.94
Price-Earnings ratio-4.94
Dividend yield
Dividend yield
Average volume
1.33M
Average volume1.33M
High today
$35.35
High today$35.35
Low today
$33.52
Low today$33.52
Open price
$34.21
Open price$34.21
Volume
1.43M
Volume1.43M
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $35.20, with a market capitalization of 2.06B. The stock trades at a price-to-earnings (P/E) ratio of -4.94.

During the trading session on 2026-04-03, Agios(AGIO) shares reached a daily high of $35.35 and a low of $33.52. At a current price of $35.20, the stock is +5.0% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 1.43M, compared to an average daily volume of 1.33M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 3d
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update

Leerink thinks Agios Pharmaceuticals’ (AGIO) announcement that it is filing mitapivat for accelerated approval in sickle cell disease has positive readthrough t...

Simply Wall St 3d
Why Agios Pharmaceuticals Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing

Agios Pharmaceuticals recently disclosed that, following a pre-supplemental New Drug Application meeting, it will seek U.S. accelerated approval for mitapivat i...

Why Agios Pharmaceuticals Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing
Benzinga 3d
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?

Agios Pharmaceuticals stock is charging ahead with explosive momentum. What’s driving AGIO stock higher? Accelerated Approval Path Gives Agios A Clearer Regulat...

Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

Nasdaq 3d
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

Key Points Agios Pharmaceuticals’ mitapivat has shown tremendous promise as a treatment for sickle cell disease. It’s been so promising, in fact, that the U.S...

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Nasdaq 3d
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

Key Points 2,959 shares sold for a total of ~$82,000 at a weighted average price of around $27.80 per share on March 5, 2026. The transaction represented 36.5...

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Seeking Alpha 3d
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion

Shares of Agios Pharmaceuticals (AGIO) rose ~14% on Tuesday after the company announced plans to seek U.S. accelerated approval for a label expansion of its lea...

Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.